Mural Oncology PLCNASDAQ:MURA
- LAST PRICE3.9900
- TODAY'S CHANGE (%)-0.0500 (-1.2376%)
- Bid / Lots4.0000/ 2
- Ask / Lots4.0700/ 6
- Open / Previous Close4.0700 / 4.0400
- Day Range
- 52 Week Range
- Volume125,281
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MURA |
|---|---|---|
| 09:32 ET | 7514 | 4.05 |
| 09:33 ET | 1036 | 4.075 |
| 09:35 ET | 150 | 4.0201 |
| 09:37 ET | 400 | 4.09 |
| 09:39 ET | 2347 | 4.07 |
| 09:48 ET | 100 | 4.09 |
| 09:50 ET | 100 | 4.0583 |
| 09:51 ET | 170 | 4.03 |
| 09:53 ET | 1000 | 4.03 |
| 09:55 ET | 423 | 4.07 |
| 09:57 ET | 2739 | 4.125 |
| 10:00 ET | 739 | 4.1275 |
| 10:02 ET | 4750 | 4.12 |
| 10:04 ET | 200 | 4.11 |
| 10:06 ET | 2000 | 4.1 |
| 10:08 ET | 827 | 4.11 |
| 10:09 ET | 600 | 4.11 |
| 10:11 ET | 500 | 4.1255 |
| 10:15 ET | 121 | 4.1308 |
| 10:20 ET | 500 | 4.12 |
| 10:22 ET | 3000 | 4.11 |
| 10:26 ET | 1563 | 4.11 |
| 10:27 ET | 632 | 4.09 |
| 10:29 ET | 524 | 4.0712 |
| 10:31 ET | 2155 | 4.07 |
| 10:36 ET | 200 | 4.095 |
| 10:38 ET | 159 | 4.0649 |
| 10:45 ET | 1729 | 4.06 |
| 10:47 ET | 2768 | 4.08 |
| 10:49 ET | 340 | 4.08 |
| 10:51 ET | 100 | 4.08 |
| 10:54 ET | 2002 | 4.04 |
| 11:02 ET | 1814 | 4.05 |
| 11:03 ET | 1000 | 4.0712 |
| 11:07 ET | 250 | 4.06 |
| 11:09 ET | 2245 | 4.1 |
| 11:14 ET | 2500 | 4.09 |
| 11:20 ET | 2913 | 4.07 |
| 11:21 ET | 400 | 4.0751 |
| 11:25 ET | 100 | 4.09 |
| 11:30 ET | 431 | 4.105 |
| 11:32 ET | 651 | 4.11 |
| 11:34 ET | 700 | 4.1 |
| 11:36 ET | 13250 | 4.07 |
| 11:38 ET | 100 | 4.06 |
| 11:39 ET | 2000 | 4.055 |
| 11:43 ET | 1639 | 4.0543 |
| 11:48 ET | 906 | 4.07 |
| 11:50 ET | 250 | 4.07 |
| 11:52 ET | 2487 | 4.05 |
| 11:57 ET | 3499 | 4.02 |
| 11:59 ET | 1600 | 4.0321 |
| 12:01 ET | 400 | 4.045 |
| 12:03 ET | 120 | 4.01 |
| 12:08 ET | 248 | 4.0362 |
| 12:10 ET | 100 | 4.01 |
| 12:12 ET | 400 | 4.035 |
| 12:15 ET | 800 | 4.05 |
| 12:17 ET | 1108 | 4 |
| 12:19 ET | 2400 | 4.01 |
| 12:21 ET | 400 | 4 |
| 12:24 ET | 2163 | 4.01 |
| 12:26 ET | 1210 | 4 |
| 12:30 ET | 298 | 3.9828 |
| 12:32 ET | 550 | 3.98 |
| 12:37 ET | 600 | 4.01 |
| 12:39 ET | 100 | 3.9814 |
| 12:44 ET | 770 | 4.02 |
| 12:46 ET | 10288 | 4.015 |
| 12:48 ET | 300 | 4.01 |
| 12:50 ET | 2500 | 4 |
| 12:51 ET | 699 | 4 |
| 12:53 ET | 200 | 4.0099 |
| 12:55 ET | 1833 | 4 |
| 12:57 ET | 2800 | 4 |
| 01:00 ET | 2943 | 3.99 |
Nov 20, 2024
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer, from 4:15PM ET on Wednesday Nov 20, 2024 by Dow Jones
4:15PM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 14, 2024
DJ Mural Oncology Price Target Maintained With a $18.00/Share by HC Wainwright & Co., from 5:00AM ET on Thursday Nov 14, 2024 by Dow Jones
5:00AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 13, 2024
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress, from 7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 13, 2024 by Dow JonesPress Release: Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress, from 7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 11, 2024
Mural Oncology to Participate in Two Upcoming Investor Conferences, from 7:00AM ET on Monday Nov 11, 2024 by Dow Jones
7:00AM ET on Monday Nov 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mural Oncology PLC | 68.9M | -0.4x | --- |
Exicure Inc | 69.5M | -13.1x | --- |
Citius Oncology Inc | 67.0M | 3.8x | --- |
X4 Pharmaceuticals Inc | 66.4M | -4.6x | --- |
Immuneering Corp | 66.1M | -1.1x | --- |
Unicycive Therapeutics Inc | 70.4M | -3.5x | --- |
Company Information
Mural Oncology plc is Ireland-based clinical-stage oncology company. The Company is leveraging its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. It leverages its in-cytokine biology, immune cell modulation and protein engineering capabilities to develop immunotherapies. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. Its portfolio of programs includes Nemvaleukin alfa (Nemvaleukin)-IL-2, IL-12, and IL-18. Nemvaleukin is an engineered interleukin-2 (IL-2) variant designed to harness the potent anti-cancer capabilities of high-dose rhIL-2 while minimizing toxicity by selectively activating cancer-fighting CD8 T cells and NK cells. The tumor-targeted split IL-12 program focuses on delivering the therapeutic potential of IL-12 by splitting it into inactive component.
Contact Information
- Headquarters
- 10 Earlsfort TerraceDUBLIN, Ireland D02 T380
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Scott Jackson
- President, Chief Executive Officer, Director
- Caroline Loew
- Chief Financial Officer
- Adam Cutler
- Chief Medical Officer
- Vicki Goodman
- Chief Legal Officer
- Maiken Keson-Brookes
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $68.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 17.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-9.14 |
Book Value | $15.81 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
